+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 70Years
All Genders
ID05863234

Phase III Study of Continuous Intravenous PPMX-T003 for Treating Aggressive NK Cell Leukemia in Adults

Led by Hiroshima University Hospital · Updated on 2025-04-30

7

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase III dose-escalation study to assess the tolerability, safety, efficacy, and pharmacokinetics of PPMX-T003 in patients with aggressive NK-cell leukemia. This study aims to better understand how this investigational treatment works and its effects in this serious condition. The research is sponsored by Hiroshima University Hospital. Participants will receive PPMX-T003, administered as a continuous intravenous infusion. The study includes multiple courses of treatment, with the first course lasting 7 days and further courses up to a maximum of 35 days. The trial does not include a placebo group and is open-label, meaning both researchers and participants know the treatment being given. During the study, participants will be monitored for adverse events and dose-limiting toxicities, particularly in the first 7 days after initial administration. Efficacy will be evaluated through liver volume assessed by CT scans, liver function tests, survival duration at 6 months, and the ability to transition to chemotherapy. Blood samples will be taken to measure drug concentration and immune response. The entire participation duration includes these monitoring and assessment periods up to six months.

CONDITIONS

Brief Title

Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Research Team

K

Kiyoshi Ando

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here